Phibro Animal Health Corporation - Class A Common Stock (PAHC)

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) fell short of the markets revenue expectations in Q1 CY2026, with sales flat year on year at $347.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.46 billion at the midpoint. Its non-GAAP profit of $0.63 per share was 8.3% below analysts’ consensus estimates.

Discover how Phibro Animal Health (PAHC) combines strong technical trends with accelerating earnings and revenue growth, signaling a potential high-momentum investment.

Phibro Animal Health (PAHC) stock shows strong technical & fundamental momentum, meeting Minervini's Trend Template with high growth in earnings and sales.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major benchmark indices were largely mixed.

Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.

Phibro Animal Health gains JPMorgan upgrade as analyst forecasts continued growth across key livestock products and long-term fundamentals.

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.